Ravi Vij

503 total citations
13 papers, 171 citations indexed

About

Ravi Vij is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Ravi Vij has authored 13 papers receiving a total of 171 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hematology, 5 papers in Molecular Biology and 4 papers in Oncology. Recurrent topics in Ravi Vij's work include Multiple Myeloma Research and Treatments (12 papers), Protein Degradation and Inhibitors (5 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Ravi Vij is often cited by papers focused on Multiple Myeloma Research and Treatments (12 papers), Protein Degradation and Inhibitors (5 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Ravi Vij collaborates with scholars based in United States, Germany and United Kingdom. Ravi Vij's co-authors include Alvin Wong, Rubén Niesvizky, Ashraf Badros, Thomas Martin, Jeffrey A. Zonder, Lori Kunkel, Jesse Keller, John F. DiPersio, H. Jean Khoury and R Brown and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Leukemia.

In The Last Decade

Ravi Vij

10 papers receiving 170 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ravi Vij United States 4 137 117 60 11 9 13 171
Luca Bertamini Italy 8 148 1.1× 124 1.1× 94 1.6× 15 1.4× 13 1.4× 15 175
Georgi Mihaylov Bulgaria 8 157 1.1× 119 1.0× 77 1.3× 20 1.8× 8 0.9× 22 205
Max Flogegård Sweden 6 51 0.4× 45 0.4× 68 1.1× 13 1.2× 8 0.9× 9 112
Katarina Uttervall Sweden 8 202 1.5× 122 1.0× 121 2.0× 31 2.8× 9 1.0× 25 229
Vadim Doronin Russia 7 155 1.1× 134 1.1× 82 1.4× 40 3.6× 18 2.0× 19 218
A. Keith Stewart United States 5 221 1.6× 184 1.6× 118 2.0× 37 3.4× 8 0.9× 13 257
Pilar Martínez‐Sánchez Spain 7 69 0.5× 50 0.4× 58 1.0× 24 2.2× 18 2.0× 18 129
Pia Sondergeld Germany 4 220 1.6× 139 1.2× 135 2.3× 40 3.6× 8 0.9× 4 252
José-María Arguiñano Spain 2 125 0.9× 104 0.9× 55 0.9× 15 1.4× 9 1.0× 4 128
Christopher Maisel United States 7 89 0.6× 79 0.7× 53 0.9× 15 1.4× 17 1.9× 20 127

Countries citing papers authored by Ravi Vij

Since Specialization
Citations

This map shows the geographic impact of Ravi Vij's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ravi Vij with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ravi Vij more than expected).

Fields of papers citing papers by Ravi Vij

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ravi Vij. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ravi Vij. The network helps show where Ravi Vij may publish in the future.

Co-authorship network of co-authors of Ravi Vij

This figure shows the co-authorship network connecting the top 25 collaborators of Ravi Vij. A scholar is included among the top collaborators of Ravi Vij based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ravi Vij. Ravi Vij is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Slade, Michael, Abir Khaled, Mark A. Fiala, et al.. (2025). Blood-Based Measurable Residual Disease by Clonotypic Mass Spectrometry is Prognostic in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant. Clinical Lymphoma Myeloma & Leukemia. 25(9). e628–e637.e4.
2.
Baljević, Muhamed, Peter M. Voorhees, Anita D’Souza, et al.. (2025). Long-term efficacy and safety of etentamig, a B-cell maturation antigen (BCMA) bispecific antibody in patients with relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 43(16_suppl). 7527–7527. 2 indexed citations
3.
Voorhees, Peter M., Anita D’Souza, Alfred Chung, et al.. (2024). Efficacy, safety, and determination of RP2D of ABBV-383, a BCMA bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 42(16_suppl). 7531–7531. 8 indexed citations
4.
5.
Weisel, Katja, Anita D’Souza, David D. Hurd, et al.. (2023). P862: A PHASE 1 FIRST-IN-HUMAN MONOTHERAPY STUDY OF ABBV-383, A BCMA × CD3 BISPECIFIC T-CELL–REDIRECTING ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA. HemaSphere. 7(S3). e0036307–e0036307. 1 indexed citations
6.
7.
8.
Vij, Ravi, et al.. (2015). Targeted treatments for multiple myeloma: specific role of carfilzomib. Pharmacogenomics and Personalized Medicine. 8. 23–23. 18 indexed citations
9.
10.
Badros, Ashraf, Ravi Vij, Thomas Martin, et al.. (2013). Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia. 27(8). 1707–1714. 116 indexed citations
11.
Leduc, Renee, Marybeth Nelson, Amy Sam, et al.. (2009). A573 Phase I Trial of CCI-779 and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma. Clinical Lymphoma & Myeloma. 9. S86–S86. 1 indexed citations
12.
Jagannath, Sundar, Ravi Vij, George Somlo, et al.. (2009). A377 Phase II Study of Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (PX-171-003). Clinical Lymphoma & Myeloma. 9. S61–S61. 1 indexed citations
13.
Khoury, H. Jean, Kathryn Trinkaus, M-J Zhang, et al.. (2003). Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation. Biology of Blood and Marrow Transplantation. 9(11). 714–721. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Luca Bertamini Breakdown of academic impact, for papers by Georgi Mihaylov Breakdown of academic impact, for papers by Max Flogegård Breakdown of academic impact, for papers by Katarina Uttervall Breakdown of academic impact, for papers by Vadim Doronin Breakdown of academic impact, for papers by A. Keith Stewart Breakdown of academic impact, for papers by Pilar Martínez‐Sánchez Breakdown of academic impact, for papers by Pia Sondergeld Breakdown of academic impact, for papers by José-María Arguiñano Breakdown of academic impact, for papers by Christopher Maisel
Rankless by CCL
2026